前列腺癌治疗靶点及相关药物药理药效学评估体系  

Therapeutic Targets for Prostate Cancer and Evaluation System for Pharmacology and Pharmacodynamics of Related Drugs

作　　者：王华倩[1] 李想[1] 邓胜城 何华红 郑希[3] 郑多[4] 蒋晟[5] 王霆 

机构地区：[1]广东工业大学AllanH.Conney抗癌药物研究实验室,广东广州510006 [2]广州市口岸药检所药理室,广东广州510160 [3]广东工业大学AllanH.Conney 抗癌药物研究实验室,广东广州510006 [4]深圳大学医学部,广东深圳518052 [5]中国科学院广州生物医药和健康研究院,广东广州510530 [6]广州威尔曼新药研发中心,广东广州510630

出　　处：《药学进展》2014年第7期507-514,共8页Progress in Pharmaceutical Sciences

摘　　要：前列腺癌一直是欧美男性高发疾病,在我国尤其是经济发达城市,近年来其发病率随着社会老年化进程加速而呈迅猛上升之势。据估,未来10年,我国前列腺癌的发病或将进入高峰期,成为男性第1大癌症杀手。目前前列腺癌尤其是晚期前列腺癌治疗药物的疗效有限且毒副作用较大,是困扰临床医生和患者的难题,故开发高效低毒的抗前列腺癌药物具有重要的现实意义。综述前列腺癌治疗靶点以及包含体内外模型和临床疗效评估指标的抗前列腺癌药物药理药效学评估体系,为前列腺癌治疗药物的研究与开发提供参考。High incidence of prostate cancer （PCa） always exists in men in Europe and America. In China, the incidence has trended towards rapid rising with the acceleration of the social aging process especially in the developed cities in recent years. It is estimated that the peak incidence will occur and PCa will become the largest cancer killer in men in the next lO years. Now the lack of efficacy and much toxic side effects of the drugs for the treatment of PCa, especially for advanced PCa, are the most disturbing problem tbr doctors and patients. So the development of anti-prostate cancer drugs with high efficacy and low toxicity has important practical significance. The therapeutic targets for prostate cancer and the evaluation system for pharmacology and pharmacodynamics of related drugs, including in vivo and in vitro model and clinical efficacy evaluation criteria, have been summarized here so as to provide reference for the research and development of anti-prostate cancer drugs. .

关 键 词：前列腺癌 治疗靶点 体内外模型 临床疗效评估指标 

分 类 号：R737.25[医药卫生—肿瘤] R96[医药卫生—临床医学]